REN and heart failure: Because of their demonstrated cardio- and renoprotective effects in reducing the risk of kidney failure and cardiovascular mortality and morbidity, renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational therapy in the management of chronic kidney disease (CKD) and heart failure (HF) [1–3].